David E Cohn MD MBA FACHE
Gynecologic Oncology
Interim Chief Executive Officer Chief Medical Officer, Arthur G. James Cancer Hospital Director, Division of Gynecologic Oncology Professor, Department of Obstetrics and Gynecology Ohio State University College of Medicine
Join to View Full Profile
1145 Olentangy River RdColumbus, OH 43212
Phone+1 614-293-3873
Fax+1 614-293-3078
Dr. Cohn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University Fisher College of BusinessMBA, 2018 - 2020
Washington University/B-JH/SLCH ConsortiumFellowship, Gynecologic Oncology, 1998 - 2001
University of WashingtonResidency, Obstetrics and Gynecology, 1994 - 1998
Georgetown University School of MedicineClass of 1994
Certifications & Licensure
OH State Medical License 2001 - 2027
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
American College of Healthcare ExecutivesFACHE
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2005 Jan 01
- Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy Start of enrollment: 2008 Apr 01
- Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery for Endometrial Robotics Versus Laparotomy Start of enrollment: 2009 May 01
- Join now to see all
Publications & Presentations
PubMed
- Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).Husam A Alqaisi, David E Cohn, Jing-Yi Chern, Linda R Duska, Andrea Jewell
Clinical Cancer Research. 2025-03-17 - Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?Paulina Haight, Caroline Bilbe, Courtney Riedinger, Floor Backes, Kristin Bixel
Gynecologic Oncology. 2025-02-18 - Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings.Paulina J Haight, Ashwini Esnakula, Courtney J Riedinger, Adrian A Suarez, Jessica Gillespie
NPJ Precision Oncology. 2025-02-08
Journal Articles
- Endometrial Carcinoma Recurrence According to Race and Ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 StudyM L Pearl, D S Miller, W T Creasman, P H Thaker, J F Boggess, S R Guntupalli, D G Mutch, J L Walker, O B Ioffe, D E Cohn, L S Downs, International Journal of Cancer
Press Mentions
Ohio State James Cancer Hospital Partners with Columbus Community Oncology PracticeDecember 16th, 2024- Should I Get the COVID-19 Booster?September 17th, 2021
- Dublin Cancer Survivor Reacts to CDC's Recommendation for Third COVID-19 Vaccine DoseAugust 13th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
